Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10442273 | 0.78 | CA2 (0.38) | TSHR | |
| SCHEMBL8743993 | 0.77 | CYP2D6 (0.33) | TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL27830812 | 0.77 | — | — | |
| SCHEMBL17469430 | 0.77 | CHRM1 (0.35) | TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2035661 | 0.77 | CHRM1 (0.35) | TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10442036 | 0.76 | MAPT (0.42) | TSHR | |
| SCHEMBL7638052 | 0.75 | CHRM1 (0.33) | TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14534529 | 0.75 | CA1 (0.37) | TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3473720 | 0.75 | CA1 (0.37) | TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4800961 | 0.75 | ALDH1A1 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554240-B1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | EP | disclosed |
| US-7351857-B2 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| CN-100354259-C | Substituted tetralins and indanes and their use | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | disclosed |
| CN-100349864-C | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA NV (BE) | 2007-11-21 | — | — | CN | disclosed |
| US-20060247314-A1 | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| CN-1798732-A | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-05 | — | — | CN | disclosed |
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| CN-1726188-A | Treatment of syndrome X with substituted 1,2,3, 4-tetrahydronaphthalenes and indanes | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-25 | — | — | CN | disclosed |
| CN-1726187-A | Substituted tetralins and indanes and their use | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-25 | — | — | CN | disclosed |
| EP-1569897-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1556344-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1554240-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-20 | — | — | EP | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | TSHR 253/4885CYP2D6 3046/4885CYP2C9 2412/4885 |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | TSHR 150/4885CYP2D6 1858/4885CYP2C9 910/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | TSHR 253/4885CYP2D6 3046/4885CYP2C9 2412/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | TSHR 253/4885CYP2D6 3046/4885CYP2C9 2412/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | TSHR 150/4885CYP2D6 1858/4885CYP2C9 910/4885 |
| US-20060247314-A1 | Substituted tetralins and indanes | PPARA, PPARG, PPARD | TSHR 282/4885CYP2D6 2172/4885CYP2C9 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.